Investor Presentaiton

Investor Presentation First six months of 2018 Slide 85 The obesity pipeline consists of projects addressing both appetite reduction and energy expenditure How to address obesity from a medical perspective Novo Nordisk obesity products and pipeline Status: 2018 expected: Weight reduction by reducing food intake Weight reduction by increasing energy expenditure Appetite reduction changing diabetes Impact on metabolic changes to increase lipid and glucose metabolism Projects: SaxendaⓇ semaglutide - QW GLP-1 - G530L glucagon analogue Launched Phase 2 Discontinued Phase 3 AM833 amylin analogue PYY1562 - PYY analogue Phase 1b Phase 1b Phase 2 ready Phase 1b1 NN9499 FGF21 obesity NN9277-GG-co-agonist Discontinued Phase 1a Phase 1b NN9423 - Tri-agonist 1706 Phase 1a Phase 1b Energy expenditure Appetite reduction Appetite reduction and energy expenditure 1 Phase 1b completed with monotherapy, phase 1b in combination with semaglutide planned for 2018 Phase 1a: Single-dose trials; Phase 1b: Multiple-dose trials QW: Once-weekly novo nordisk

View entire presentation